Every year, an estimated 60-70 million people are affected by gastrointestinal diseases in the U.S. alone.1 Across the world, novel therapies are desperately needed in both gastroenterology and hepatology. We have a dedicated 800-strong gastroenterology/hepatology team who understand the broad spectrum of digestive disorders.
Specializing in Phase I to IV studies, we help to bring a diverse range of therapies to an equally diverse range of markets, delivering projects ranging from strategic clinical development planning to single- or multi-phase clinical programs.
We work closely with gastroenterologists, hepatologists, primary care investigators and Key Opinion Leaders across the globe to ensure that the strategies we develop for you are built on the best network and knowledge in the business.
Our adult and pediatric clinical study experience includes anal fissures, celiac disease, colitis, colorectal disorders, constipation disorders, diverticulitis, gastroenteritis, gastroesophageal reflux disease (GERD), gastric surgery (including band devices), gastric ulcers, hepatic cirrhosis/fibrosis, inflammatory bowel disease (IBD) including Crohn’s Disease and ulcerative colitis, irritable bowel syndrome (IBS), non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), nausea and vomiting, pancreatitis, and short bowel syndrome.
We Make it Easier to Recruit the Right Patients
The gastroenterology and hepatology therapeutic areas are saturated with choice for patients and physicians. High availability of existing treatment makes recruitment for clinical studies challenging. Physicians and patients can choose to receive a marketed product with known safety and effectiveness or risk receiving a placebo in a clinical study.
We can help you find the most appropriate investigators and sites to help you find the patients your trial needs. We speak their language and it shows. Investigative sites voted us “Top CRO to Work With” among top 10 global CROs in the 2017 CenterWatch Global Investigative Site Relationship Survey.
We have some of the strongest experience in the industry in optimizing patient compliance and have relationships with all of the providers of state-of-the-art Patient Reported Outcomes (PRO) tools, such as handheld diaries and IXRS systems.
We Have the Up-to-Date Knowledge You Need
In the fast-moving field of gastroenterology/hepatology, it’s essential to be knowledgeable about the latest developments in research. Our team of CRAs work exclusively in this area and keep abreast of new information through training and hands-on experience.
For example, we are providing development strategy and logistical support to a number of companies working on the nascent field of gut microbiome modification. We also understand the complex and changing protocols for the treatment of Crohn’s disease and ulcerative colitis globally and are involved in several nutrition studies as well.
1 Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology. 2009; 136:376–386. [PubMed: 19124023]